Palbociclib as one of the CDK4/6 inhibitors is of undisputed importance to women with advanced HR+/HER2- breast cancer

Abstract

Cyclin dependent kinase (CDK4/6) inhibitors block cell division (G1 to S phase) by acting on CDK4/6. Palbociclib in combination with aromatase inhibitors or in combination with fulvestrant contributes to prolonging the time to progression in patients with locally advanced or metastatic hormone receptor positive and HER2 negative breast cancer.

Keywords

• Breast cancer
• targeted therapy